Trusted Resources: News & Meetings
Latest announcements and gatherings
Regenxbio Presents Positive Initial Data From Phase I/II Trial Of Rgx-111 for the Treatment of Severe MPS I at 18th Annual World Symposium™ 2022
REGENXBIO Inc. (Nasdaq: RGNX) today announced positive interim data are being presented at the 18th Annual WORLDSymposium™ from five patients in the ongoing Phase I/II trial and one patient from a single-patient Investigational New Drug (IND) application of RGX-111 for the treatment of severe Mucopolysaccharidosis Type I (MPS I).
RGX-111 is an investigational one-time gene therapy designed to deliver the gene that encodes the IDUA enzyme using the AAV9 vector. RGX-111 is administered directly to the CNS. The primary endpoint of the trial is to evaluate the safety of RGX-111. Secondary and exploratory endpoints include biomarkers of α-l-iduronidase (IDUA) enzyme activity in the cerebrospinal fluid (CSF), serum and urine, neurodevelopmental assessments, and caregiver reported outcomes.
BookmarkRelated Content
-
A Guide to Understanding MPS II (Hunter Syndrome)MPS II belongs to a group of inherited m...
-
Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler SyndromeAllogeneic hematopoietic stem-cell trans...
-
Mucopolysaccharidoses (MPS) and Gene TherapyMucopolysaccharidoses (MPS) are a group ...
-
Ultrasound Findings of Finger, Wrist and Knee Joints in Mucopolysaccharidosis Type IMusculoskeletal findings in MPS can prog...
-
Mucopolysaccharidosis Type I Diagnosed by Aortic and Mitral Valve ReplacementA 32-year-old developmentally delayed ma...
-
EMA Grants Orphan Drug Designation to JR-171 for the Treatment of Mucopolysaccaridosis Type I (MPS I)JCR Pharmaceuticals Co., Ltd. announced ...
-
The MPS I-H Diagnostic Journeyhttps://www.youtube.com/watch?v=jSq5tQD4...
Powered by
